When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, ...

Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, ...

which it can use to buy companies with promising R&D programs. It expects top-line growth in 2025 to be driven by Keytruda, especially in early-stage cancers, new products Welireg, Winrevair and ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

Today, the Governments of Canada and the province of Ontario signed the National Strategy for Drugs for Rare Disease (DRD) agreement to invest over ...

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

Welireg has a mechanism of action somewhat similar ... our tools and find the best investible stocks, complete with buy/sell strategies and alerts. Sign up now for our free trial, request access ...

For the estimated 56 to 90 people in Ontario who will be diagnosed with this rare condition each year, public drug coverage for this drug will be in the order of $35,000 for ... Health Canada has ...

Public drug coverage for this drug will be in the order of $35,000 for the first treatment ... Health Canada has authorized Welireg to treat von Hippel-Lindau (VHL) disease in adults, an inherited ...

The regulatory agency will review MSD’s new drug application (NDA) for Welireg under a Priority Review, with a Prescription ...